123STA T . 212 7PUBLIC LA W 111 –80—O CT. 21 , 200 9(E)informat ionont he metho d o l o g ie s to im p ro v e inter - agen cy coordination b et w een host governments , the W orld F ood P rogram, and non-governmental organi z ation to develop more consistent estimates of food aid needs and the n u mber of intended recipients to appropriately inform the purchases of commodities and in order to appropriately plan for commodity procurement for food aid programs
( 2 ) provide the matter described under subsection ( 1 )of this section in the form of a consensus report under the signa- tures of the S ecretaries of A griculture, State, and T ranspor- tation; and ( 3 ) estimates and cost savings analysis for this section shall be derived from periods representative of normal program operations . S EC . 7 3 8 . There is hereby appropriated $ 2 50 ,000, to remain available until e x pended, for a grant to the K ansas Farm B ureau Foundation for wor k -force development initiatives to address out- migration in rural areas. SEC. 73 9 . There is hereby appropriated $800,000 to the Farm Service Agency to carry out a pilot program to demonstrate the use of new technologies that increase the rate of growth of re- forested hardwood trees on private non-industrial forests lands, enrolling lands on the coast of the G ulf of M exico that were damaged by H urricane Katrina in 2005. SEC. 7 4 0. (a) The C ommissioner of Food and D rugs shall estab- lish within the Food and Drug Administration a review group which shall recommend to the Commissioner of Food and Drugs appropriate preclinical, trial design, and regulatory paradigms and optimal solutions for the prevention, diagnosis, and treatment of rare diseases
- Provide
d , That the Commissioner of Food and Drugs shall appoint individuals employed by the Food and Drug Adminis- tration to serve on the review group: Provided fu r th er, That mem- bers of the review group shall have specific expertise relating to the development of articles for use in the prevention, diagnosis, or treatment of rare diseases, including specific expertise in devel- oping or carrying out clinical trials. (b) The Commissioner of Food and Drugs shall establish within the Food and Drug Administration a review group which shall recommend to the Commissioner of Food and Drugs appropriate preclinical, trial design, and regulatory paradigms and optimal solu- tions for the prevention, diagnosis, and treatment of neglected diseases of the developing world: Provided, That the Commissioner of Food and Drugs shall appoint individuals employed by the Food and Drug Administration to serve on the review group: Provided further, That members of the review group shall have specific expertise relating to the development of articles for use in the prevention, diagnosis, or treatment of neglected diseases of the developing world, including specific expertise in developing or car- rying out clinical trials: Provided further, That for the purposes of this section the term ‘ ‘neglected disease of the developing world ’ ’ means a tropical disease, as defined in section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U .S.C. 3 6 0n(a)(3)). (c) The Commissioner of Food and Drugs shall — (1) submit, not later than 1 year after the date of the establishment of review groups under subsections (a) and (b), Reports.D e adlin es. E sta b lis hm ent. 21USC360 aa note. Reports.
